139 related articles for article (PubMed ID: 38539574)
1. Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial.
Bailey S; André N; Gandola L; Massimino M; Wheatley K; Gates S; Homer V; Rutkowski S; Clifford SC
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539574
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial.
Bailey S; André N; Gandola L; Massimino M; Wheatley K; Gates S; Homer V; Rutkowski S; Clifford SC
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053536
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma.
Mynarek M; Milde T; Padovani L; Janssens GO; Kwiecien R; Mosseri V; Clifford SC; Doz F; Rutkowski S
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885186
[TBL] [Abstract][Full Text] [Related]
5. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.
Dietzsch S; Braesigk A; Seidel C; Remmele J; Kitzing R; Schlender T; Mynarek M; Geismar D; Jablonska K; Schwarz R; Pazos M; Weber DC; Frick S; Gurtner K; Matuschek C; Harrabi SB; Glück A; Lewitzki V; Dieckmann K; Benesch M; Gerber NU; Obrecht D; Rutkowski S; Timmermann B; Kortmann RD
Strahlenther Onkol; 2022 Mar; 198(3):282-290. PubMed ID: 34351451
[TBL] [Abstract][Full Text] [Related]
6. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma : First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial.
Dietzsch S; Braesigk A; Seidel C; Remmele J; Kitzing R; Schlender T; Mynarek M; Geismar D; Jablonska K; Schwarz R; Pazos M; Walser M; Frick S; Gurtner K; Matuschek C; Harrabi SB; Glück A; Lewitzki V; Dieckmann K; Benesch M; Gerber NU; Rutkowski S; Timmermann B; Kortmann RD
Strahlenther Onkol; 2021 Aug; 197(8):674-682. PubMed ID: 33226469
[TBL] [Abstract][Full Text] [Related]
8. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
[TBL] [Abstract][Full Text] [Related]
10. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study.
Sabel M; Fleischhack G; Tippelt S; Gustafsson G; Doz F; Kortmann R; Massimino M; Navajas A; von Hoff K; Rutkowski S; Warmuth-Metz M; Clifford SC; Pietsch T; Pizer B; Lannering B;
J Neurooncol; 2016 Sep; 129(3):515-524. PubMed ID: 27423645
[TBL] [Abstract][Full Text] [Related]
11. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary treatment of medulloblastoma: a 5-year experience with the SIOP trial.
Gerosa MA; di Stefano E; Olivi A; Carteri A
Childs Brain; 1981; 8(2):107-18. PubMed ID: 7018855
[TBL] [Abstract][Full Text] [Related]
13. A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy.
Meroni S; Cavatorta C; Barra S; Cavagnetto F; Scarzello G; Scaggion A; Pecori E; Diletto B; Alessandro O; Massimino M; Gianolini S; Pignoli E; Gandola L
Strahlenther Onkol; 2019 Sep; 195(9):843-850. PubMed ID: 31025053
[TBL] [Abstract][Full Text] [Related]
14. CO-FISH, COD-FISH, ReD-FISH, SKY-FISH.
Williams ES; Cornforth MN; Goodwin EH; Bailey SM
Methods Mol Biol; 2011; 735():113-24. PubMed ID: 21461816
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
Goddard J; Castle J; Southworth E; Fletcher A; Crosier S; Martin-Guerrero I; García-Ariza M; Navajas A; Masliah-Planchon J; Bourdeaut F; Dufour C; Ayrault O; Goschzik T; Pietsch T; Sill M; Pfister SM; Rutkowski S; Richardson S; Hill RM; Williamson D; Bailey S; Schwalbe EC; Clifford SC; Hicks D
Acta Neuropathol; 2023 May; 145(5):651-666. PubMed ID: 37014508
[TBL] [Abstract][Full Text] [Related]
16. Surgery for recurrent medulloblastoma: A review.
Rolland A; Aquilina K
Neurochirurgie; 2021 Feb; 67(1):69-75. PubMed ID: 31351079
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.
Bailey CC; Gnekow A; Wellek S; Jones M; Round C; Brown J; Phillips A; Neidhardt MK
Med Pediatr Oncol; 1995 Sep; 25(3):166-78. PubMed ID: 7623725
[TBL] [Abstract][Full Text] [Related]
18. [Medulloblastoma therapy studies MBL 80 and MED 84 of the Society of Pediatric Oncology and the Société Internationale d'Oncologie Pédiatrique (SIOP)].
Neidhardt M; Bailey CC; Gnekow A; Kleihues P; Michaelis J; Wellek S
Klin Padiatr; 1987; 199(3):188-92. PubMed ID: 3306131
[TBL] [Abstract][Full Text] [Related]
19. [Differentiation of medulloblastoma: immunohistochemistry of 247 cases from the therapy trial SIOP/GPO MED 84].
Aguzzi A; Wiestler OD; Kleihues P
Verh Dtsch Ges Pathol; 1988; 72():284-7. PubMed ID: 3218344
[No Abstract] [Full Text] [Related]
20. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts.
Freeman CR; Taylor RE; Kortmann RD; Carrie C
Med Pediatr Oncol; 2002 Aug; 39(2):99-108. PubMed ID: 12116057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
